Breathlessness and opioid prescribing in COPD in general practice: a cross-sectional, observational study.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
31
10
2019
accepted:
15
04
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
Chronic breathlessness is a disabling syndrome, prevalent in people with advanced chronic obstructive pulmonary disease (COPD). Regular, low-dose, oral sustained-release morphine is approved in Australia to reduce symptomatic chronic breathlessness. We aimed to determine the current prescribing patterns of opioids for chronic breathlessness in COPD in Australian general practice and to define any associated patient and practitioner characteristics. Five years (2011 to 2016) of the Bettering the Evaluation and Care of Health database, an Australian national, continual, cross-sectional study of clinical care in general practice were used. The database included 100 consecutive clinical encounters from almost 1000 general practitioners annually (n=488 100 encounters). Descriptive analyses with subsequent regression models were generated. Breathlessness as a patient-defined reason for encounter was identified in 621 of 4522 encounters where COPD was managed. Opioids were prescribed in 309 of 4522 encounters where COPD was managed (6.8%; (95% CI) 6.1-7.6), of which only 17 were prescribed for breathlessness, and the rest for other conditions almost entirely related to pain. Patient age (45-64 years
Identifiants
pubmed: 32775398
doi: 10.1183/23120541.00299-2019
pii: 00299-2019
pmc: PMC7402382
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©ERS 2020.
Déclaration de conflit d'intérêts
Conflict of interest: D.C. Currow reports that he is an unpaid advisory board member for Helsinn Pharmaceuticals. He is a paid consultant and receives payment for intellectual property with Mayne Pharma and is a consultant with Specialised Therapeutics Australia Pty. Ltd. Conflict of interest: M.J. Johnson has nothing to disclose. Conflict of interest: A. Pollack has nothing to disclose. Conflict of interest: D.H. Ferreira has nothing to disclose. Conflict of interest: S. Kochovska has nothing to disclose. Conflict of interest: M. Ekström has nothing to disclose. Conflict of interest: C. Harrison has nothing to disclose.
Références
Thorax. 2018 Jan;73(1):88-90
pubmed: 28377491
Thorax. 1999 Jul;54(7):581-6
pubmed: 10377201
Thorax. 2013 Sep;68(9):867-79
pubmed: 23204065
Palliat Support Care. 2007 Sep;5(3):281-302
pubmed: 17969832
BMJ. 2015 Jan 02;350:g7617
pubmed: 25556037
Thorax. 2002 Nov;57(11):939-44
pubmed: 12403875
Ann Am Thorac Soc. 2015 Jul;12(7):1079-92
pubmed: 25803110
J Palliat Med. 2012 Jul;15(7):744-50
pubmed: 22687264
J Pain Symptom Manage. 2009 Oct;38(4):533-45
pubmed: 19822276
Eur Respir J. 2017 May 25;49(5):
pubmed: 28546269
BMJ Support Palliat Care. 2018 Dec;8(4):411-420
pubmed: 29353252
Commun Dis Intell Q Rep. 2003;27(3):391-3
pubmed: 14510069
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005623
pubmed: 18425927
BMC Pulm Med. 2019 May 16;19(1):95
pubmed: 31096982
Can Respir J. 2011 Mar-Apr;18(2):69-78
pubmed: 21499589
PLoS One. 2013 Sep 17;8(9):e74814
pubmed: 24069352
Thorax. 2017 Dec;72(12):1151-1153
pubmed: 28356419
J Clin Med Res. 2011 Oct;3(5):239-46
pubmed: 22383911
Eur Respir J. 2018 Feb 21;51(2):
pubmed: 29467199
Int J Chron Obstruct Pulmon Dis. 2016 Oct 21;11:2651-2657
pubmed: 27799763
Thorax. 2020 Jan;75(1):50-56
pubmed: 31558624
Eur Respir J. 2016 Sep;48(3):683-93
pubmed: 27418553
PLoS One. 2013 Dec 02;8(12):e80095
pubmed: 24312456
Eur J Gen Pract. 2016 Dec;22(4):240-246
pubmed: 27652899